Evidence map›Paper›PMID 35689544›Full record

ArticleCancer science2022

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.

Takayuki Ikezoe, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, Naoko Hosono, Yasuyoshi Morita, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, Keisuke Matsubara and 4 more

Open access · goldAbstract readMulticenter StudyClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 1 country.

Takayuki IkezoeDepartment of Hematology, Fukushima Medical University Hospital, Fukushima, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University, Tokyo, Japan.
Masahiro OnozawaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Takahisa YamaneDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Naoko HosonoDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
Yasuyoshi MoritaDepartment of Hematology and Rheumatology, Kindai University Hospital, Osaka-Sayama, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Hiromi IwasakiDepartment of Hematology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science Faculty of Medicine, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-6533-1594
Keisuke MatsubaraSumitomo Pharma Co., Ltd., Tokyo, Japan.
Saori SugimotoSumitomo Pharma Co., Ltd., Tokyo, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0003-3683-7147
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Kyushu University · JPSumitomo Chemical (Japan) · JPChugoku Central Hospital · JPFukushima Medical University Hospital · JPHokkaido University Hospital · JPKindai University Hospital · JPNagasaki University · JPNational Kyushu Medical Center · JPOsaka City General Hospital · JPSocial Insurance Saitama Chuo Hospital · JPTokai University · JPUniversity of Fukui Hospital · JP

Funding

Sumitomo Pharma
6 · The paper itself

Abstract

Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment-refractory (R/R) AML or newly diagnosed patients with poor prognostic factors. Alvocidib (DSP-2033), a potent cyclin-dependent kinase 9 inhibitor, has previously demonstrated promising clinical activity for the treatment of AML. In this multicenter, open-label, uncontrolled, 3 + 3 phase I study, we investigated the safety and tolerability of alvocidib administered in combination with either cytarabine and mitoxantrone (ACM) for R/R AML or cytarabine/daunorubicin (A + 7 + 3) for newly diagnosed AML. Alvocidib was administered to all patients as a 30-min intravenous (i.v.) bolus (30 mg/m

Indexed as

CytarabineLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsDaunorubicinHumansJapanRemission InductionCytarabineDaunorubicinalvocidibclinical trialJapanleukemia, myeloidsafety

Identifiers

PMID35689544
PMCPMC9746059
OpenAlexW4282935857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.